References: A practical guide to antiproteinuric drugs in dogs

1.

Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.

Am J Physio

l 1981;241:F85-F93.

2.

Brown SA, Finco DR, Crowell WA, et al. Single-nephron adaptations to partial renal ablation in the dog.

Am J Physiol

1990;258:F495-503.

3.

Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney.

J Am Soc Nephro

l 1999;10 Suppl 12:S258-S265.

4.

Tylicki L, Lizakowski S, Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.

J Nephrol

2012;25:900-910.

5.

Wynn TA. Cellular and molecular mechanisms of fibrosis.

J Pathol

2008;214:199-210.

6.

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).

Lancet

1997;349:1857-1863.

7.

Ruggenenti P, Pagano E, Tammuzzo L, et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.

Kidney Int

2001;59:286-294.

8.

Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Lancet

1999;354:359-364.

9.

Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis.

J Vet Intern Med

2000;14:526-533.

10.

Lees GE, Brown SA, Elliott J, et al. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal).

J Vet Intern Med

2005;19:377-385.

11.

Brown SA, Finco DR, Brown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency.

Am J Vet Res

2003;64:321-327.

12.

Brown SA, Walton CL, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.

Kidney Int

1993;43:1210-1218.

13.

Tenhündfeld J, Wefstaedt P, Nolte IJ. A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs.

J Am Vet Med Asso

c 2009;234:1031-1037.

14.

DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Med Toxicol

1986;1:122-141.

15.

Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.

J Eval Clin Pract

2004;10:499-509.

16.

Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.

J Vet Intern Med

1998;12:93-95.

17.

Lefebvre HP, Jeunesse E, Laroute V, et al. Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.

J Vet Intern Med

2006;20:499-507.

18.

Lefebvre HP, Laroute V, Concordet D, et al. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.

J Vet Intern Med

1999;13:21-27.

19.

Tocco DJ, deLuna FA, Duncan AE, et al. The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Drug Metab Dispos

1982;10:15-19.

20.

Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors.

Am J Health Syst Pharm

2000;57 Suppl 1:S3-S7.

21.

Moesgaard SG, Pedersen LG, Teerlink T, et al. Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation.

J Vet Intern Med

2005;19:712-719.

22.

Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.

J Am Soc Nephro

l 2007;18:1889-1898.

23.

Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Diabetologia

2009;52:46-49.

24.

Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.

Ann Intern Med

1991;115:513-519.

25.

Brooks DP, DePalma PD, Ruffolo RR. Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.

J Pharmacol Exp Ther

1992;263:422-427.

26.

Devoy MAB, Tomson CRV, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible.

J Intern Med

1992;232:493-498.

27.

Schlesinger DP, Rubin SI. Potential adverse effects of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.

Compend Contin Educ Vet Pract

1994;16:275-283.

28.

Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.

Circulation

2000;101:844-846.

29.

Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5:408-417.

30.

Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.

Am J Kidney Dis

2001;37:477-483.

31.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

New Engl J Med

2004;351:1952-1961.

32.

Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

Kidney Int

1994;45:861-867.

33.

Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.

Kidney Int

2008;74:364-369.

34.

Christ DD, Wong PC, Wong YN, et al. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.

J Pharmacol Exp Ther

1994;268:1199-1205.

35.

Heller J, Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin-converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog.

Kidney Blood Press Res

1997;20:391-397.

36.

Wu MY, Ma XJ, Yang C, et al. Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals

. Acta Pharmacol Si

n 2009;30:307-313.